<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Contact Us Select Models
Select Models
1437919905

Analytical Assays For Endpoint Data Collection

Next Generation Sequencing (NGS) Services

51

Overview

Preclinical NGS Services, Now with HT-RNA-Seq

Champions' experts can help you integrate Whole Exome Sequencing (WES), RNA sequencing (RNA-Seq), Digital RNA with pertUrbation of Genes sequencing (DRUG-seq), or Whole Transcriptome Sequencing (WTS) into your preclinical studies or clinical trials to discover endless insights.

Tissue processing is available following post-study completion at our US-based facility

Fast turnaround times with reliable, high-quality data analysis

Data analysis and visualization are delivered through Lumin or analyzed by Champions' dedicated team of bioinformaticians

New

High-Throughput RNA-Seq (HT-RNA-Seq)

We are now offering HT-RNA-Seq, a scale-up transcriptomics assay built for in vivo studies. It delivers the same core biological insight as traditional bulk RNA-Seq, at a meaningfully lower cost per sample, so you can profile significantly more models, treatment arms, and timepoints within the same study budget. 

HT-RNA-Seq

In a recent in vivo resistance study, HT-RNA-Seq identified distinct transcriptional signatures separating durable responders from tumors developing acquired resistance, giving researchers a mechanistic, biomarker-level view of resistance as it emerges.  

Features

  • Profile substantially more PDX models for the same budget compared to traditional bulk RNA-Seq
  • Supports large-scale drug response profiling, biomarker discovery, and model stratification across hundreds of samples in a single study
  • Delivers the same gene-expression, differential expression, and pathway-enrichment insight as bulk RNA-Seq; best suited for studies that do not require isoform- or splice-level resolution
  • Turnaround of approximately 4 to 8 weeks from receipt of your last sample
Contact us to scope an HT-RNA-Seq study for your program
49

Uncover Deep Molecular Insights using Preclinical Next Generation Sequencing

Next Generation Sequencing (NGS) can be utilized as an endpoint for in vivo and ex vivo studies to provide a deeper understanding of the model to better stratify responders versus non-responders and to discover novel biomarkers to guide patient selection. 

In particular, DRUG-seq can be used to study an agent's effect on the transcriptome and investigate mechanisms of action and profiles of drug response and resistance, using limited starting material.

As oncology experts, our team has deep scientific competencies to not only aid in the planning of your upcoming in vivo or ex vivo study, but to recommend NGS endpoint analyses that can help you discover powerful insights with your therapeutic candidate from our highly characterized tumor bank.

Resources

Explore our resources

Next Generation Sequencing (NGS) is an innovative technology that has revolutionized oncology research. Specifically, with NGS technology researchers are able to quickly sequence all exons in a genome (Whole Exome Sequencing or WES) and utilize RNA sequencing (RNA-Seq) to discover novel RNA variants and quantify mRNA for differential gene expression analysis. 

Tab Imges_Medium27

FAQ

Frequently Asked Questions

HT-RNA-Seq is Champions' scale-up transcriptomics assay, built specifically for in vivo studies that need to cover more ground within a fixed budget. It captures the same core biological insight as traditional bulk RNA-Seq (gene expression, differential expression, and pathway enrichment) using a 384-well workflow that allows samples to be pooled and processed at much greater scale. The trade-off is coverage depth: HT-RNA-Seq reads the 3' end of transcripts rather than sequencing full-length, so it is not the right choice for isoform or splice-variant analysis. For the large majority of studies focused on gene-level expression changes rather than splicing detail, that trade-off has no practical impact on the results. Turnaround is typically 4 to 8 weeks from receipt of your last sample. 

Champions offers a full suite of next-generation sequencing services for preclinical oncology research, including Whole Exome Sequencing (WES), RNA sequencing (RNA-Seq), Whole Transcriptome Sequencing (WTS), and our new high-throughput HT-RNA-Seq platform for studies that need to profile more models, arms, or timepoints within the same budget. Data analysis and visualization are delivered through Lumin or by Champions' dedicated team of bioinformaticians, so you can go from raw sequencing data to actionable biomarker and mechanism-of-action insights without building that capability in-house. 
1437919905

Get started

Request a study

Fill out the form to get more information regarding Colony Forming Unit Assays